Study of sintilimab, ramucirumab, and chemo for stomach cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (sintilimab and ramucirumab) plus chemotherapy as a first treatment for stomach cancer that has spread to the liver. It aims to see if this triple therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach, gastroesophageal junction, or esophageal cancer that has spread to the liver.
- Your cancer is HER2-negative (a specific protein test).
- You have not had any previous chemotherapy or targeted therapy for your advanced cancer (except if you had prior treatment over 6 months ago and it came back).
- You are able to provide tumor tissue, blood, and stool samples for research.
- You have good liver function (liver enzymes within 5 times the normal upper limit).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, ramucirumab, and paclitaxel) for people with stomach cancer that returned soon after finishing initial chemotherapy. The goal is to see if this combination can help control the cancer and improve outcomes.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests a combination of two medicines (sintilimab and FOLFIRI) as a second option for people with advanced stomach cancer that no longer responds to first treatment. It aims to see if this combination can help control the cancer.
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.